By sequencing the coding regions of about 20,000 genes in the whole exome of tumor tissue and white blood cell control with high-throughput sequencing technology, and combining with whole transcription sequencing, comprehensive and accurate detect gene mutations related to tumor occurrence and development or clinical treatment. At the same time, it can be used for the detection and analysis of immunotherapy-related markers such as MSI, TMB, TNB, and HLA-LOH, high-quality neoantigen prediction, and detection and analysis of positive and negative mutations related to immunotherapy, providing reference and guidance for the clinical dosing regimens of tumor patients.
▪ Has the only neoantigen algorithm in China validated by the Tumor Neoantigen Selection Alliance (TESLA)
▪ Whole exome + whole transcriptome sequencing significantly improving the detection sensitivity of fusion mutations
▪ Sequencing depth higher than the consensus of clinical experts
▪ The mutation information is accurately described according to the HGVS standard terms. The germline genetic mutations are classified according to the ACMG guidelines for the classification of the pathogenicity of mutations, and the clinical medication is suggested based on clinical based medical evidence
Copyright©2021
Shenzhen yucebio Technology Co., Ltd. all rights reserved
Yueicp no.16128839
